Compare DNUT & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNUT | VOR |
|---|---|---|
| Founded | 1937 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 602.2M | 562.6M |
| IPO Year | 2021 | 2021 |
| Metric | DNUT | VOR |
|---|---|---|
| Price | $3.45 | $16.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | $4.72 | ★ $64.78 |
| AVG Volume (30 Days) | ★ 2.4M | 618.2K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | N/A | ★ 2.86 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,522,616,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.58 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.58 | $0.13 |
| 52 Week High | $5.92 | $49.95 |
| Indicator | DNUT | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 51.63 | 60.22 |
| Support Level | $3.11 | $11.27 |
| Resistance Level | $3.48 | $16.95 |
| Average True Range (ATR) | 0.19 | 1.14 |
| MACD | 0.05 | 0.09 |
| Stochastic Oscillator | 43.50 | 75.99 |
Krispy Kreme Inc is a sweet treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-your-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations across the globe. It derives maximum revenue from the U.S. segment.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.